Bayer takes control of Loxo duo as Lilly closes takeoverBayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the Share XBayer takes control of Loxo duo as Lilly closes takeoverhttps://pharmaphorum.com/news/bayer-control-loxo-duo-lilly-takeover/
Bayer/Orion showcase results from prostate cancer challengerBayer and development partner Orion have released detailed results from the trial that will form the backbone of Share XBayer/Orion showcase results from prostate cancer challengerhttps://pharmaphorum.com/news/bayer-orion-showcase-results-from-prostate-cancer-challenger/
Merck’s Keytruda gets boost in kidney and head and neck cancerMerck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Share XMerck’s Keytruda gets boost in kidney and head and neck cancerhttps://pharmaphorum.com/news/mercks-keytruda-gets-boost-in-kidney-and-head-and-neck-cancer/
Grey Wolf raises £10m for tumour ‘illumination’ techImmuno-oncology biotech Grey Wolf Therapeutics has raised £10 million in series A financing to develop therapies that increase Share XGrey Wolf raises £10m for tumour ‘illumination’ techhttps://pharmaphorum.com/news/grey-wolf-raises-10m-for-tumour-illumination-tech/
GSK bolts-on immuno-oncology candidate with €3.7bn Merck dealGlaxoSmithKline is making another big play in cancer, signing a wide-ranging deal with Merck KGaA for M7824, an Share XGSK bolts-on immuno-oncology candidate with €3.7bn Merck dealhttps://pharmaphorum.com/news/gsk-bolts-on-immuno-oncology-candidate-with-e3-7bn-merck-deal/
Oncology round-up: CAR-T conference raises hopes for solid tumour therapyKisaco Research’s CAR-T Congress EU could not have come at a better time – the day after it Share XOncology round-up: CAR-T conference raises hopes for solid tumour therapyhttps://pharmaphorum.com/views-and-analysis/oncology-round-up-car-t-conference-raises-hopes-for-solid-tumour-therapy/
Doctors and patient groups struggle with CAR-T ‘hype’Managing patients’ expectations of CAR-T therapies is proving to be a huge challenge from when selection decisions are Share XDoctors and patient groups struggle with CAR-T ‘hype’https://pharmaphorum.com/news/doctors-and-patient-groups-struggle-with-car-t-hype/
CAR-T firms push to improve manufacturing efficiencyExperience with the approved CAR-T drugs from Novartis and Gilead has shown that being able to manufacture enough Share XCAR-T firms push to improve manufacturing efficiencyhttps://pharmaphorum.com/news/car-t-firms-push-to-improve-manufacturing-efficiency/
Hope for CAR-T combination that could tackle solid tumoursGetting CAR-T cells to work in solid tumours is proving a tough nut to crack – and a Share XHope for CAR-T combination that could tackle solid tumourshttps://pharmaphorum.com/news/hope-for-car-t-combination-that-could-tackle-solid-tumours/
